Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Thermo Fisher Scientific delivered solid Q1 FY2026 results with revenue of $11.0B (+6.2% YoY), net income of $1.65B (+9.6% YoY), and a significant jump in operating cash flow (+64.9% YoY), though long-term debt surged 26.4% reflecting major acquisition activity.
Revenue
$11.01B
+6.18% YoY
EPS (Diluted)
$4.43
+11.31% YoY
Operating Income
$1.86B
+8.57% YoY
Source: SEC XBRL
Thermo Fisher Scientific (TMO) reported Q1 FY2026 revenue of $11.01B, up 6.2% year over year. Operating margin was 16.9%, up 0.3 points from 16.6% a year earlier. Operating cash flow was $1.19B, up 64.9% year over year. TMO's fiscal Q1 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 6.03 | 5.77 | Beat +4.5% |
| Mar 2026This filing | 5.44 | 5.29 | Beat +2.8% |
| Dec 2025 | 6.57 | 6.51 | Beat +0.9% |
| Sep 2025 | 5.79 | 5.55 | Beat +4.4% |
Adjusted (non-GAAP) EPS of $5.44 versus the $5.29 analyst consensus — a +2.8% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $4.43.
Compiled by AI from this SEC filing
TMO grew total revenue to $11.0B in Q1 FY2026, up $641M or 6.2% year-over-year from $10.36B, demonstrating continued demand for its life sciences products and services despite a challenging macro environment.
Source: 10-Q Income Statement, Q1 FY2026
Operating income rose 8.6% to $1.86B, outpacing revenue growth and expanding operating margin modestly to 16.93% from 16.56% in the prior year period, indicating improving cost efficiency and operating leverage.
Source: 10-Q Income Statement, Q1 FY2026
Operating cash flow surged 64.9% year-over-year to $1.19B from $723M, a significant improvement that signals stronger working capital management and earnings quality in Q1 FY2026.
Source: 10-Q Cash Flow Statement, Q1 FY2026
Total assets expanded 14.4% to $113.3B while long-term debt jumped 26.4% to $42.9B from $34.0B, and investing cash outflows ballooned to -$8.96B from -$527M, strongly suggesting a large acquisition was completed during the quarter.
Source: 10-Q Balance Sheet & Cash Flow Statement, Q1 FY2026
TMO repurchased $3.0B in shares during Q1 FY2026, a 50% increase from $2.0B in the prior year period, reflecting continued commitment to returning capital to shareholders even while funding significant M&A activity.
Source: 10-Q Cash Flow Statement, Q1 FY2026
Compiled by AI from this SEC filing · 3 high, 2 medium, 0 low
Long-term debt surged 26.4% to $42.9B in Q1 FY2026, likely tied to a major acquisition. This elevated leverage increases interest expense burden and reduces financial flexibility, particularly if integration costs exceed expectations or revenue synergies are delayed.
Source: 10-Q Balance Sheet, Q1 FY2026
Cash and equivalents fell 21.3% year-over-year to $3.25B while the company simultaneously executed $3.0B in buybacks and ~$8.96B in investing activities. This rapid cash deployment could constrain liquidity if operating conditions deteriorate.
Source: 10-Q Balance Sheet & Cash Flow Statement, Q1 FY2026
Current liabilities grew 11.0% to $14.6B while current assets declined 4.5% to $22.3B, compressing the current ratio to 1.53. While still above 1.0, the trend indicates tightening near-term liquidity that warrants monitoring.
Source: 10-Q Balance Sheet, Q1 FY2026
The scale of investing outflows (-$8.96B vs. -$527M prior year) implies a transformative acquisition. Large integrations carry execution risk including cultural misalignment, IT system complexity, and potential goodwill impairment if the acquired business underperforms.
Source: 10-Q Cash Flow Statement, Q1 FY2026
Selling, general and administrative expenses rose 5.0% to $2.18B, growing nearly in line with revenue. Sustained SG&A inflation could limit further margin expansion if revenue growth moderates, particularly given the added overhead from newly acquired operations.
Source: 10-Q Income Statement, Q1 FY2026
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 11.01 $B | 10.36 $B | +6.18% |
Operating Income $B | 1.86 $B | 1.72 $B | +8.57% |
Net Income $B | 1.65 $B | 1.51 $B | +9.56% |
EPS (Basic) $ | 4.44 $ | 3.99 $ | +11.28% |
EPS (Diluted) $ | 4.43 $ | 3.98 $ | +11.31% |
R&D Expense $M | 336.00 $M | 342.00 $M | -1.75% |
SG&A Expense $B | 2.18 $B | 2.08 $B | +4.96% |
Answers draw on this SEC filing and the data on this page
Thermo Fisher Scientific reported strong Q2 FY2026 financial results, with revenue increasing 10.5% YoY to $11.99B and diluted EPS rising 9.3% YoY to $4.68, driven by robust pharma and biotech market demand and strategic M&A integration.
Thermo Fisher Scientific delivered solid FY2025 growth with revenue rising 3.9% to $44.6B and net income up 5.8% to $6.7B, while a significant acquisition drove a 26.1% increase in long-term debt and a 145.7% surge in cash balances.
Other companies in Life Sciences Tools & Services